Article

Preoperative topical NSAID yields improved phaco efficiency

Washington, DC—The introduction of a topical nonsteroidal anti-inflammatory drug (NSAID) 3 days before phacoemulsification produced excellent results in terms of surgical efficacy and outcomes, according to Eric D. Donnenfeld, MD, at the American Society of Cataract and Refractive Surgery annual meeting.

Washington, DC-The introduction of a topical nonsteroidal anti-inflammatory drug (NSAID) 3 days before phacoemulsification produced excellent results in terms of surgical efficacy and outcomes, according to Eric D. Donnenfeld, MD, at the American Society of Cataract and Refractive Surgery annual meeting.

He found that treatment with ketorolac begun 3 days before surgery significantly improved the maintenance of pupil size, phacoemulsification time and energy, operative time, corneal clarity, postoperative inflammation, and intraoperative and postoperative discomfort.

Outcomes with treatment begun 3 days before surgery were significantly better (p < 0.01) than results with treatment begun 1 day in advance, which in turn were significantly better than either when treatment was begun 1 hour before surgery or when patients were given placebo (p < 0.01), said Dr. Donnenfeld, who is also a partner in a private practice in Long Island, NY.

Primary outcome measures were as follows:

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.